Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 23, pp. 2145-2158
Open Access | Times Cited: 447

Showing 1-25 of 447 citing articles:

Cancer statistics, 2024
Rebecca L. Siegel, Angela N. Giaquinto, Ahmedin Jemal
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 1, pp. 12-49
Open Access | Times Cited: 3805
FIGO staging of endometrial cancer: 2023
Jonathan S. Berek, Xavier Matías‐Guiu, Carien L. Creutzberg, et al.
International Journal of Gynecology & Obstetrics (2023) Vol. 162, Iss. 2, pp. 383-394
Open Access | Times Cited: 463
FIGO staging of endometrial cancer: 2023
Jonathan S. Berek, Xavier Matías‐Guiu, Carien L. Creutzberg, et al.
Journal of Gynecologic Oncology (2023) Vol. 34, Iss. 5
Open Access | Times Cited: 121
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 3, pp. 283-299
Open Access | Times Cited: 119
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
Giorgio Bogani, Bradley J. Monk, Matthew A. Powell, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 414-428
Closed Access | Times Cited: 35
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1135-1146
Closed Access | Times Cited: 26
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
M.A. Powell, Line Bjørge, Lyndsay Willmott, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 728-738
Open Access | Times Cited: 22
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
Toon Van Gorp, David Cibula, Weiguo Lv, et al.
Annals of Oncology (2024) Vol. 35, Iss. 11, pp. 968-980
Closed Access | Times Cited: 20
Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment
Holly Baker‐Rand, Sarah Kitson
Cancers (2024) Vol. 16, Iss. 5, pp. 1028-1028
Open Access | Times Cited: 16
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion
Shouyan Deng, Yibo Zhang, Huanbin Wang, et al.
Cell (2024) Vol. 187, Iss. 9, pp. 2305-2323.e33
Closed Access | Times Cited: 15
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
Sandro Pignata, Daniela Califano, D. Lorusso, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 667-676
Closed Access | Times Cited: 15
The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment
Luigi Antonio De Vitis, Gabriella Schivardi, Susanna Delfrati, et al.
International Journal of Gynecological Cancer (2025) Vol. 35, Iss. 1, pp. 100024-100024
Closed Access | Times Cited: 1
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres
Richard Schwameis, Francesco Fanfani, Christoph Ebner, et al.
European Journal of Cancer (2023) Vol. 193, pp. 113317-113317
Open Access | Times Cited: 39
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4564-4574
Open Access | Times Cited: 31
Therapeutic Antibodies in Medicine
Prerna Sharma, Rahul V. Joshi, Robert C. Pritchard, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6438-6438
Open Access | Times Cited: 28
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Ignace Vergote, José Alejandro Pérez Fidalgo, Erika Hamilton, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 35, pp. 5400-5410
Open Access | Times Cited: 28
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors
Philipp Knopf, Dimitri Stowbur, Sabrina H. L. Hoffmann, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Characterization of mismatch‐repair/microsatellite instability‐discordant endometrial cancers
Courtney J. Riedinger, Ashwini Esnakula, Paulina Haight, et al.
Cancer (2023) Vol. 130, Iss. 3, pp. 385-399
Closed Access | Times Cited: 25
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
Ilaria Colombo, Katherine Karakasis, Suku Sneha, et al.
Cancers (2023) Vol. 15, Iss. 12, pp. 3220-3220
Open Access | Times Cited: 23
Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection
Natalia Galant, Paweł Krawczyk, Marta Monist, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5893-5893
Open Access | Times Cited: 13
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer
Alessandro D. Santin, Bradley R. Corr, Alexander I. Spira, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 29, pp. 3421-3429
Closed Access | Times Cited: 12
2023 FIGO staging system for endometrial cancer: The evolution of the revolution
David K. Gaffney, Xavier Matías‐Guiu, David G. Mutch, et al.
Gynecologic Oncology (2024) Vol. 184, pp. 245-253
Closed Access | Times Cited: 11
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy
Te-An Lee, En-Yun Tsai, Shou-Hou Liu, et al.
Cancer Research (2024) Vol. 84, Iss. 6, pp. 800-807
Open Access | Times Cited: 10
Recent Therapeutic Advances in Gynecologic Oncology: A Review
Elise Wilson, Ramez N. Eskander, Pratibha Binder
Cancers (2024) Vol. 16, Iss. 4, pp. 770-770
Open Access | Times Cited: 10
Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer
Núria Agustí, Alexa Kanbergs, Roni Nitecki
Gynecologic Oncology (2024) Vol. 185, pp. 121-127
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top